Table 4.
Genotyping and allele distributions in control subjects and patients with CAD in the Uygur population
| |
Total |
Men |
Women |
||||||
|---|---|---|---|---|---|---|---|---|---|
| Variants | CAD patients | Control subjects | P value | CAD patients | Control subjects | P value | CAD patients | Control subjects | P value |
|
rs1996147 |
|
|
|
|
|
|
|
|
|
| Genotyping |
|
|
|
|
|
|
|
|
|
| AA |
109(36.5%) |
75(24.7%) |
|
77(38.9%) |
49(25.0%) |
|
32(31.7%) |
26(24.3%) |
|
| AG |
142(47.5%) |
156(51.5%) |
|
90(45.5%) |
98(50.0%) |
|
52(51.5%) |
58(54.2%) |
|
| GG |
48(16.0%) |
72(23.8%) |
0.003* |
31(15.6%) |
49(25.0%) |
0.005* |
17(16.8%) |
23(21.5%) |
0.433 |
| Dominant model |
|
|
|
|
|
|
|
|
|
| GG |
48(16.0%) |
72(23.8%) |
|
31(15.6%) |
49(25.0%) |
|
17(16.8%) |
23(21.5%) |
|
| AA + AG |
251(84.0%) |
231(76.2%) |
0.018* |
167(84.4%) |
147(75.0%) |
0.021* |
84(83.2%) |
84(78.5%) |
0.394 |
| Recessive model |
|
|
|
|
|
|
|
|
|
| AA |
109(36.5%) |
75(24.7%) |
|
77(38.9%) |
49(25.0%) |
|
32(31.7%) |
26(24.3%) |
|
| GG + AG |
190(63.5%) |
228(75.3%) |
0.002* |
121(61.1%) |
147(75.0%) |
0.003* |
69(68.3%) |
81(75.7%) |
0.235 |
| Additive model |
|
|
|
|
|
|
|
|
|
| AG |
142(47.5%) |
156(51.5%) |
|
90(45.5%) |
98(50.0%) |
|
52(51.5%) |
58(54.2%) |
|
| AA + GG |
157(52.5%) |
147(48.5%) |
0.327 |
108(54.5%) |
98(50.0%) |
0.366 |
49(48.5%) |
49(45.8%) |
0.694 |
| Allele |
|
|
|
|
|
|
|
|
|
| A |
360(60.2%) |
306(50.5%) |
|
244(61.6%) |
196(50.0%) |
|
116(57.4%) |
110(51.4%) |
|
| G |
238(39.8%) |
300(49.5%) |
0.001* |
152(38.4%) |
196(50.0%) |
0.001* |
86(42.6%) |
104(48.6%) |
0.218 |
|
rs1008949 |
|
|
|
|
|
|
|
|
|
| Genotyping |
|
|
|
|
|
|
|
|
|
| CC |
118(39.5%) |
104(34.3%) |
|
77(38.9%) |
66(33.7%) |
|
41(40.6%) |
38(35.5%) |
|
| CT |
136(45.5%) |
152(50.2%) |
|
95(48.0%) |
98(50.0%) |
|
41(40.6%) |
54(50.5%) |
|
| TT |
45(15.0%) |
47(15.5%) |
0.409 |
26(13.1%) |
32(16.3%) |
0.472 |
19(18.8%) |
15(14.0%) |
0.334 |
| Dominant model |
|
|
|
|
|
|
|
|
|
| CC |
118(39.5%) |
104(34.3%) |
|
77(38.9%) |
66(33.7%) |
|
41(40.6%) |
38(35.5%) |
|
| TT + CT |
181(60.5%) |
199(65.7%) |
0.191 |
121(61.1%) |
130(66.3%) |
0.282 |
60(59.4%) |
69(64.5%) |
0.451 |
| Recessive model |
|
|
|
|
|
|
|
|
|
| TT |
45(15.0%) |
47(15.5%) |
|
26(13.1%) |
32(16.3%) |
|
19(18.8%) |
15(14.0%) |
|
| CC + CT |
254(85.0%) |
256(84.5%) |
0.875 |
172(86.9%) |
164(83.7%) |
0.371 |
82(81.2%) |
92(86.0%) |
0.350 |
| Additive model |
|
|
|
|
|
|
|
|
|
| CT |
136(45.5%) |
152(50.2%) |
|
95(48.0%) |
98(50.0%) |
|
41(40.6%) |
54(50.5%) |
|
| CC + TT |
163(54.5%) |
151(49.8%) |
0.267 |
103(52.0%) |
98(50.0%) |
0.688 |
60(59.4%) |
53(49.5%) |
0.153 |
| Allele |
|
|
|
|
|
|
|
|
|
| C |
372(62.2%) |
360(59.4%) |
|
249(62.9%) |
230(58.7%) |
|
123(60.9%) |
130(60.7%) |
|
| T | 226(37.8%) | 246(40.6%) | 0.319 | 147(37.1%) | 162(41.3%) | 0.227 | 79(39.1%) | 84(39.3%) | 0.976 |
CAD, coronary artery disease; SNP, single-nucleotide polymorphism; *P < 0.05.